Efficacy and safety of tenofovir/emtricitabine compared to abacavir/lamivudine in HIV-1 infected patients in clinical setting. The TEAL study
Journal of the International AIDS Society volume 11, Article number: P79 (2008)
Limited direct comparative data exist between the recommended dual NRTI fixed dose combinations, tenofovir/emtricitabine (Truvada) and abacavir/lamivudine (Kivexa). A recent study (HEAT) evaluated these dual NRTI backbones with a boosted PI. However, there are no data comparing these two formulations when used with other antiretroviral drugs.
Retrospective study of HIV-1 infected patients in two Genito-Urinary Medicine clinics. Patients taking either Truvada or Kivexa were included. Data including previous treatment, resistance test, HLA B5701 status, pre-treatment CD4 count, plasma viral load, age, ethnicity, renal function, lipid profiles were gathered. Primary endpoint was the proportion of subjects with viral load <50 copies/ml at 48 weeks.
Truvada was non-inferior to Kivexa in this cohort. However, virological failure was observed in three patients when Kivexa was used with an NNRTI. Median CD4 increase was greater in Truvada arm at 48 weeks but this was not statistically significant. Further data will be presented at the meeting.
About this article
Cite this article
Eccleston, K., Bambumba, A., Babu, C. et al. Efficacy and safety of tenofovir/emtricitabine compared to abacavir/lamivudine in HIV-1 infected patients in clinical setting. The TEAL study. JIAS 11 (Suppl 1), P79 (2008). https://doi.org/10.1186/1758-2652-11-S1-P79
- Viral Load
- Virological Failure
- Fixed Dose Combination
- Plasma Viral Load
- B5701 Status